KTC
EBS icon

Kistler-Tiffany Companies’s Emergent Biosolutions EBS Stock Holding History

Kistler-Tiffany Companies’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9
Closed – – 590
2016
Q2 		$0 Buy
+9
New +$353 ﹤0.01% 652

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kistler-Tiffany Companies's EBS Position: Q3 2016 in Review

Kistler-Tiffany Companies sold out of Emergent Biosolutions (EBS) in Q3 2016, closing a stake of 9 shares.

Kistler-Tiffany Companies first reported a position in EBS in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 204 funds tracked by Wall St. Rank hold EBS as of Q3 2016.

  • Kistler-Tiffany Companies reported no remaining Emergent Biosolutions position as of Q3 2016 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 9 Emergent Biosolutions shares in Q3 2016.
  • Kistler-Tiffany Companies first reported a position in Emergent Biosolutions in Q2 2016 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Emergent Biosolutions position peaked at $0 in Q2 2016.
  • 204 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2016.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2016, filed 8 Nov 2016.